Provided by Tiger Fintech (Singapore) Pte. Ltd.

Avidity Biosciences, Inc.

26.57
-1.5300-5.44%
Post-market: 27.080.5100+1.92%16:45 EDT
Volume:1.84M
Turnover:49.36M
Market Cap:3.19B
PE:-9.20
High:27.83
Open:26.93
Low:26.23
Close:28.10
Loading ...

Company Profile

Company Name:
Avidity Biosciences, Inc.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
391
Office Location:
10578 Science Center Drive,Suite 125,San Diego,California,United States
Zip Code:
92121
Fax:
- -
Introduction:
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease is under phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of Duchenne Muscular Dystrophy, which is under phase 1/2 clinical trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy is in phase 1/2 clinical trial. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.

Directors

Name
Position
Troy Wilson
Executive Chairman of the Board
Carsten Boess
Director
Edward Kaye
Director
Michael Martin
Director
Noreen Henig
Director
Roderick Wong
Director
Todd Brady
Director

Shareholders

Name
Position
Sarah Boyce
President and Chief Executive Officer
Joseph Baroldi
Chief Operating Officer
Michael F. MacLean
Chief Financial Officer
Arthur A. Levin
Chief Scientific Officer
Troy Wilson
Executive Chairman of the Board